Insulin degludec: A long-acting modern insulin analogue with a predictable pharmacokinetic/ pharmacodynamic profile

Drugs of Today

Volumn 49, Issue 6, 2013, Pages 387-397

  Rendell, Marc ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes type 1; Diabetes type 2; Insulin analogue; Insulin degludec; NN 1250

Indexed keywords

FATTY ACID DERIVATIVE; GLUCOSE; INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; LONG ACTING INSULIN; SHORT ACTING INSULIN;

CARDIOVASCULAR RISK; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERACTION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; META ANALYSIS (TOPIC); MISCIBILITY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SUBCUTANEOUS TISSUE;

DIABETES TYPE 1; DIABETES TYPE 2; INSULIN ANALOGUE; INSULIN DEGLUDEC; NN-1250;

DIABETES MELLITUS; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING;

EID: 84880009335     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.6.1976051     Document Type: Review

References (52)

1. Howey, D.C., Bowsher, R.R., Brunelle, R.L., Rowe, H.M., Santa, P.F., Downing-Shelton, J., Woodworth, J.R. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995, 58(4): 459-69.
2. Mudaliar, S.R., Lindberg, F.A., Joyce, M., Beerdsen, P., Strange, P., Lin, A., Henry, R.R. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999, 22(9): 1501-6. (Pubitemid 29418246)
3. Danne, T., Becker, R.H., Heise, T., Bittner, C., Frick, A.D., Rave, K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005, 28(9): 2100-5. (Pubitemid 41242451)
4. Becker, R.H., Frick, A.D., Burger, F., Potgieter, J.H., Scholtz, H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005, 113(8): 435-43. (Pubitemid 41360749)
5. Hagedorn, H.C., Jensen, B.N., Krarup, N.B., Woodstrup, I. Protamine insulin. JAMA 1936, 106: 177-80.
6. Krayenbuhl, C., Rosenberg, T. Crystalline protamine insulin. Rep Steno Mem Hosp Nord Insulinlab 1946, 1: 60-73.
7. Hallas-Moller, K., Peterson, K., Schlitchkrull, J. Crystalline amorphous insulin-zinc compounds with prolonged action. Science 1952, 116(3105): 394-98.
8. Hallas-Moller, K., Jersild, M., Peterson, K., Schlitchkrull, J. The lente insulins, insulin-zinc suspensions. Dan Med Bull 1954, 1(5): 132-42.
9. Olsson, P.O., Hans, A., Henning, V.S. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin. Diabetes Care 1987, 10(4): 473-7.
10. Bolli, G.B., Owens, D.R. Insulin glargine. Lancet 2000, 356(9228): 443-5. (Pubitemid 30496809)
11. Owens, D.R., Coates, P.A., Luzio, S.D., Tinbergen, J.P., Kurzhals, R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000, 23(6): 813-9. (Pubitemid 30414199)
12. Lepore, M., Pampanelli, S., Fanelli, C. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000, 49(12): 2142-8.
13. Scholtz, H.E., Pretorius, S.G., Wessels, D.H., Becker, R.H. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005, 48(10): 1988-95. (Pubitemid 41416907)
14. Fulcher, G.R., Gilbert, R.E., Yue, D.K. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005, 35(9): 536-42. (Pubitemid 41291382)
15. Herwig, J., Scholl-Schilling, G., Bohles, H. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin. J Pediatr Endocrinol Metab 2007, 20(4): 517-25. (Pubitemid 46865032)
16. Rossetti, P., Pampanelli, S., Fanelli, C. et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003, 26(5): 1490-6. (Pubitemid 36929184)
17. Rosenstock, J., Schwartz, S.L., Clark, C.M., Jr., Park, G.D., Donley, D.W., Edwards, M.B. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001, 24(4): 631-6. (Pubitemid 32888839)
18. Rosenstock, J., Dailey, G., Massi-Benedetti, M., Fritsche, A., Lin, Z., Salzman, A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005, 28(4): 950-5. (Pubitemid 40434505)
19. Havelund, S., Plum, A., Ribel, U., Jonassen, I., Volund, A., Markussen, J., Kurtzhals, P. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004, 21(8): 1498-504. (Pubitemid 39149667)
20. Plank, J., Bodenlenz, M., Sinner, F. et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005, 28(5): 1107-12. (Pubitemid 40616620)
21. Porcellati, F., Rossetti, P., Busciantella, N.R. et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007, 30(10): 2447-52. (Pubitemid 47547770)
22. Kolendorf, K., Ross, G.P., Pavlic-Renar, I. et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med 2006, 23(7): 729-35. (Pubitemid 44366070)
23. Hompesch, M., Troupin, B., Heise, T., Elbroend, B., Endahl, L., Haahr, H., Heinemann, L. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab 2006, 8(5): 568-73. (Pubitemid 44184251)
24. Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D.B., Wahlund, P.O., Ribel, U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012, 29(8): 2104-14.
25. Steensgaard, D.B., Schluckebier, G., Strauss, H.M. et al. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry 2013, 52(2): 295-309.
26. Jonassen, I.B., Havelund, S., Ribel, U., et al. Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Diabetes [70th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 25-29, Orlando) 2010] 2010, 59(Suppl. 1): Abst 39-OR.
27. Heise, T., Nosek, L., Nosek, L., Bottcher, S.G., Granhall, C., Haahr, H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. 71st Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 24-28, San Diego) 2011, Abst 0037-LB.
28. Danne, T., Biester, T., Blaesig, S., et al. The pharmacokinetic properties of insulin degludec in children and adolescents compared with adults with type 1 diabetes after single-dose administration. Pediatric Diabetes [37th Ann Meet Int Soc Pediatric Adolescent Diabetes (ISPAD) (Oct 19-22, Miami Beach) 2011] 2011, 12(Suppl. 15): 35-6.
29. Heise, T., Hermanski, L., Nosek, L., Feldmann, A., Rasmussen, S., Stryhn, T.K., Haahr, H. Insulin degludec: Less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia [46th Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 20-24, Stockholm) 2010] 2010, 53(Suppl. 1): Abst 971.
30. Heise, T., Hermanski, L., Nosek, L.F., A.;, Rasmussen, S., Haahr, H. The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state. 71st Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 24-28, San Diego) 2011, Abst 0960-P.
31. Jonassen, I., Hoeg-Jensen, T., Havelund, S., Ribel, U. Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation. J Pept Sci 2010, 16(Suppl. 1): 32.
32. Vaag, A., Leiter, L.A., Franek, E., et al. IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: Comparison with biphasic insulin aspart 30. 47th Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 12-16, Lisbon) 2011, Abst 1040.
33. Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., Haahr, H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012, 14(9): 859-64.
34. Zinman, B., Fulcher, G., Rao, P.V. et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011, 377(9769): 924-31.
35. CHMP assessment report. Tresiba. International non-proprietary name: insulin degludec. Procedure No. EMEA/H/C/ 002498 . European Medicines Agency Committee for Medicinal Products for Human Use (CHMP), Sept 20, 2012.
36. European Medicines Agency recommends approval of first higher-strength insulin for treatment of patients with diabetes mellitus in the EU [news release]. European Medicines Agency, October 19, 2012.
37. CHMP assessment report: Ryzodeg. International non-proprietary name: insulin degludec/insulin aspart. Procedure No. EMEA/H/C/002499 . European Medicines Agency Committee for Medicinal Products for Human Use (CHMP), October 18, 2012.
38. Zinman, B., Philis-Tsimikas, A., Cariou, B. et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012, 35(12): 2464-71.
39. Garber, A.J., King, A.B., Del Prato, S. et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012, 379(9825): 1498-507.
40. Heller, S., Buse, J., Fisher, M. et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basalbolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012, 379(9825): 1489-97.
41. Mathieu, C., Hollander, P., Miranda-Palma, B. et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013, 98(3): 1154-62.
42. Meneghini, L., Atkin, S.L., Gough, S.C. et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013, 36(4): 858-64.
43. Ratner, R.E., Gough, S.C., Mathieu, C. et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013, 15(2): 175-84.
44. Hirsch, I.B., Bode, B., Courreges, J.P. et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care 2012, 35(11): 2174-81.
45. Bonds, D.E., Miller, M.E., Bergenstal, R.M. et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340: b4909.
46. Hemmingsen, B., Lund, S.S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., Wetterslev, J. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011, 343: d6898.
47. Turnbull, F.M., Abraira, C., Anderson, R.J. et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52(11): 2288-98.
48. Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee on Insulin Degludec. Thursday, November 8, 2012 . Food and Drug Administration Center for Drug Evaluation and Research.
49. Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), December 2008.
50. Rendell, M. The path to approval of new drugs for diabetes. Expert Opin Drug Saf 2013, 12(2): 195-207.
51. Merl, V., Peters, A., Oltmanns, K.M. et al. Preserved circadian rhythm of serum insulin concentration at low plasma glucose during fasting in lean and overweight humans. Metabolism 2004, 53(11): 1449-53. (Pubitemid 39410385)
52. Rendell, M., Akturk, H.K., Tella, S.H. Glargine safety, diabetes and cancer. Expert Opin Drug Saf 2013, 12(2): 247-63.